Kruisbestuiving tussen grote bedrijven en spinoffs

Prof. Dr. Bart De Moor STADIUS, ESAT, KU Leuven

Content

- My research group STADIUS/ESAT/KU Leuven
- Our Technology Transfer Office LRD
- My spinoffs, large companies, lessons learned
 - IPCOS
 - DATA4s
 - -TML
 - Cartagenia
 - Trendminer
 - Silicos
 - Ugentec
- Conclusions













Marc Moonen

Alexander Bertrand

Jan Aerts

Bart DeMoor









Panos Patrinos

Yves Moreau

Johan Suykens

Sabine VanHuffel











Lieven DeLathauwer Bart Van Rumste **KULLOC-Geel KULAK**


Toon van Waterschoot Jos De Brabanter **KULLOC-Geel**

KULLOC-Gent

Joos Vandewalle Em. Professor

http://www.esat.kuleuven.be/stadius

PhDs, postdocs, professors (updated 04/12/2015)



STADIUS - Alumni

K. Pelckmans Uppsala Univ. Sweden







T. De Bie University of Bristol, UK

. De Schutter G. Leus M. Verhaegen TUDelft TUDelft TUDelft The Netherlands (NL)

D. Thierens Univ. Utrecht (NL)



P. Antal

Hungary

Budapest Univ.



J. Vanderschoot Univ. Leiden (NL)

S. Tan

China

Peking University,



J.M. Rabaey

Univ. of California Berkeley, CA, USA

L. Vandenberghe UCLA, CA, USA



F. Verstraete Ugent, Belgium (Odysseus fel.)



Mustak E. Yalcin Istanbul Tech.Univ. Turkey





J. Chen University of Texas Med. Branch Galveston, TX, USA



T. Laudadio IAC-CNR Bari, Italy



I. Barhumi University, Al-Ain



Oviedo National Univ. of Colombia







University of Oldenburg Germany



United Arab Emirates





S. Xavier-de-Souza Federal University of Rio Grande do Norte, Brazil



L. Lukas Catholic University of Indonesia Atma Jaya, Indonesia












Current/Accepted/Past Projects – Lenght in months



■ 12 or less ■ 12-24 ■ 24-36 ■ 36-48 ■ 48-60 ■ Longer than 60






Turn over ('small sme')


- 2010: 5.911.277 euro
- 2011: 5.626.785 euro
- 2012: 5.470.918 euro
- 2013: 5.857.540 euro
- 2014: 6.863.446 euro
- 2015: 5.516.867 euro
- 2016: 5.018.127 euro


Positive correlation in excellence for fundamental research, strategic basic research, direct contract research, tech transfer and spin-off creation !!!


STADIUS Publications per year




BOOKS


















































STADIUS 'Output': Awards

IEEE Fellows


1992 Joos Vandewalle 2004 Bart De Moor 2007 Marc Moonen 2009 Sabine Van Huffel 2015 Lieven De Lathauwer 2015 Johan Suykens





AWARDS

IEEE Fellowships



IEEE Gauss Award

IEEE Young Author Best Paper Award

IEEE Best Student Paper Award

Award at IEEE BioVis

EAMBES Fellowship

Martin Black Award

Fund for Scientific Research – Flanders, Siemens Prize (2x)

Alcatel Bell Award

International Neural Networks Society INNS

2000 Young Investigator

Celtic Excellence Award

Elsevier Editors' Choice

Elsevier Best Paper Award

Fulbright Grante - Brown University

KU Leuven Research Council Award

Laureate of the Belgium Royal Academy of Science


ERCIM Cor Baayen Award

Honorary Mention in the European Research Consortium



eltic-Plus















IPEM









ELSEVIER

Content

- My research group STADIUS/ESAT/KU Leuven
- Our Technology Transfer Office LRD
- My spinoffs, large companies, lessons learned
 - IPCOS
 - DATA4s
 - -TML
 - Cartagenia
 - Trendminer
 - Silicos
 - Ugentec
- Conclusions


Leuven Research and Development

- Founded in 1972
- Technology and knowledge transfer office of K.U.Leuven
- Bridge between university, industry and society
- Supports researchers
- Offers technologies to industry
- High level of budgetary and HR autonomy
- 'Business unit'



LRD: Mission

"Promoting and supporting knowledge and technology transfer between university and industry"




What is LRD?

- LRD consists of:
 - Central multidisciplinary staff
 - Supports researchers in knowledge and technology transfer
 - Research divisions
 - 1,340 researchers & 410 supporting
 - Embedded in university via matrix structure
 - Virtual organisations in which (groups of)
 researchers (from different faculties
 or departments) can group their
 applied research, commercialindustrial and exploitation activities.




LRD research divisions



LRD divisions/projects:
Contract and budgetary
autonomy and flexibility
incentives

Organisation



- Close interaction/collaboration between different units
- Regional and international networking


Research collaboration



- Incentives for researches:
 - Who gets what (after payment of costs)?
 - 8.5% LRD and 8.5% K.U.Leuven
 - Remaining (and largest) part of net profit flows back to research division
 - Incentive: 50% of net profit can go to individuals (rarely used)
 - What to do with built up reserves?
 - Expand research group
 - Invest in patents
 - Invest in spin-offs

Research collaboration

- 114 million euro income from research collaboration
- 1,774 new agreements (2014)



Spin-offs & innovation

- What do we do?
 - Developing <u>business plans</u>
 - Validating <u>business models</u> and the market
 - Offering <u>legal support</u>
 - Putting together a <u>competent team</u>
 - Finding investors
 - Finding <u>infrastructure</u>
 - Managing growth of spin-offs
 - Promoting <u>valorisation and</u> <u>entrepreneurship</u>
 - Stimulating <u>regional development</u>, <u>networks and clusters</u>



Incubation & seed financing

- Gemma Frisius Fund KU Leuven (GFF)
 - Seed capital for spin-off companies
 - GFF founded in 1997 & GFF II in 2002
 - At the end of 2009 GFF and GFF II merged into one single fund
 - Partners:
 - KU Leuven (20% of capital)
 - Two banks: KBC Private Equity (40%) and BNP Paribas Fortis Private Equity (40%)
 - Combination between:
 - Knowledge and technology transfer expertise (university)
 - Financial expertise (financial partners)
 - Not restricted to one technology domain
 - 27 million euro invested in 42 spin-off companies




Spin-offs & innovation

- Incentives for researchers:
 - Return through shares & warrants
 - Realise a surplus value on shares
 - Valuation of intellectual property & knowledge depends on various factors:
 - Intellectual property and contracts brought in
 - Patent portfolio
 - Time-to-market
 - Team




Spin-off companies

Cumulative number of spin-offs created




- 105 spin-off companies started, 87 still active; together
 +/- 4,100 employees (numbers 2014)
- 760 million euro external capital (2005-2014 only)
- 7 successful flotations (IPOs)

Multilevel interaction




Content

- My research group STADIUS/ESAT/KU Leuven
- Our Technology Transfer Office LRD
- My spinoffs, large companies, lessons learned
 - IPCOS
 - DATA4s
 - -TML
 - Cartagenia
 - Trendminer
 - Silicos
 - Ugentec
- Conclusions



Stadius 0&0 matrix structure

- Horizontals: data driven algorithms
 - Numerical (multi-)linear algebra
 - System identification and control
 - Digital signal processing
 - Machine Learning
 - Support Vector Machines
 - Probabilistic algorithms
 - Visualization
- Verticals
 - Digital Health
 - Industry 4.0
 - Smart Cities
 - Fintech



TRL

Industry **Smart** Digital E-Health Cities 4.0 **Economy** Signal processing & systems Data Mining Exploration Data Mining - Prediction Data Mining Visualisation

STADIUS - SPIN-OFFS "Going beyond research" www. esat.kuleuven.be/stadius/spinoffs.php



www.tmleuven.be





Data mining industry solutions

www.dsquare.be



www.cartagenia.com




Automated PCR analysis

www.ugentec.com



www.baesystems.com



www.ipcos.be



Specialized in modelling and control of multivariable industrial processes (chemical and power plants, oil exploration) automation & optimization (1995) http://www.ipcos.com/en

employees:60

Value: 9 mio

Locations: Leuven,

Eindhoven, Cambridge,

India, Abu Dhabi

- Endogeneous growth is slow
- Lucrative exclusivity deals hamper growth and business development
 - Shell
 - Co-development product
 - Opportunity and liability
 - Market, good deal
 - Potential for ultimate exit
 - Highly dependent on intransparant decision procedures
 - Years negociation to kill exclusivity
- Learn from your large partners THEIR Rol is
 - Example batch reactor 'earn back time'
 - Example chemical destillation nonsaturated market
 - Academic: genericity is an asset
 - Commercially: genericity is a curse
- Large single investors
 - KBC \rightarrow EU \rightarrow MBO





Payment fraud detection (2000)

- 2004: acquired by Norkom Technologies;
- 2011: Norkom Techn. acquired by Detica NetReveal, Bus. Division of BAE Systems Detica.

http://www.deticanetreveal.com/

en/about-us.html

- Originated in large EU project in mobile phone fraud detection
 - KPN, Orange, Proximus,...
- Taught us to understand RoI in fraud, churn, customer retention and recruiting efforts, ...
- Hence allowed us to determine our sales prices settings
- First experience with professional investors
- Corporate governance
 - External board members from industry
 - Liability for Col



Transport & Mobility

- Founded 2002
- Consulting and projects in traffic and mobility

http://www.tmleuven.be/

Employees: # 30

Turn over: 2.5 mio euro

Shares: 47 % KU Leuven,

53 % private

- Example projects
 - Oosterweel
 - 'Rekeningrijden'
 -
- Services driven company
- No 'exponential' growth rate possible
- Restricted market
- Public Procurement Procedures
- Joint venture with TNO
 - Large Dutch 'government' company
 - Were clashing with 'Latin' culture in Belgium
 - Acquired 50 % of TML
 - Sold it again to original owners ('good deal !') because of internal reorganisation: Large companies reorganize !!

:: CARTAGENIA

Data handling & mining for clinical genetics (2008)

http://www.cartagenia.com/

- # Employees: 40
- Turnover: 4 mio USD
- Locations: Leuven Boston
- Acquired by Agilent
- 7 mio / 60 mio

- Company direct result from joint venture in research
 - STADIUS: bioinformatics
 - Center Human Genetics
- Founded by 2 of my PhD students
- CEO Herman Verrelst (current Biocartis)
 - Former Data4s → Norkom
 - Former Medicim → Nobel Biocare
- 3 -4 'serious' capitalization rounds
- Rol: Market clear (after zooming to niche)
 - Software for genomics prenatal tests in human genetics centers
- Sales partnership with Agilent
 - Flirting from the beginning
 - Exit!
- Board Chair
 - Paul Van Dun (director LRD, lawyer!)



- 2008
- Data mining software & services for process industry – alarm monitoring
- won in 2009 the award of "best spin-off of the year"
- # Employees: \rightarrow 60
- Turnover: 3-4 mio
- Locations: Hasselt, NY,
 Houston, Germany
- <u>https://www.trendminer.co</u> <u>m</u>

- 'Spin-in'
- Initiated: 2 engineers (former students of mine) from BAYER and 1 PhD
- Only 1 'survives'
- Co-development with large companies
 - Several SBO/O&O projects
 - E.g. Umicore
- Board Chair former CEO of BASF
- Several capitalization round
- Profesionalization of
 - Organization (CEO Bert Baeck)
 - Shareholders and Board (Jurgen Ingels, Ducko Sickinge,...)
- New trend: large companies want part of the shares for partnership/acquisition
 - Suez
 - Innovation Fund Chemie
- Internationalization!



- 2005
- In silico drug discovery
- Activities ceased in 2012

- 'Spin-in'
- Initiated:
 - 2 pharmacologists J&J
 - 1 postdoc Stadius
- Co-development with large companies
 - Several SBO/O&O projects
- Excellent technology!
- But business model NOT ok!
 - Services to pharma
- 'Kiss of the spider woman'
 - Exclusivity
 - Non-disclosure
 - Non-scalable in partners/customizers
 - No leverage in follow-up trajectories of drug development
 - Scarce feedback (2nd opinion)

Content

- My research group STADIUS/ESAT/KU Leuven
- Our Technology Transfer Office LRD
- My spinoffs, large companies, lessons learned
 - IPCOS
 - DATA4s
 - -TML
 - Cartagenia
 - Trendminer
 - Silicos
 - Ugentec
- Conclusions

Conclusies: Interactie met grote bedrijven

- Verbreed het perspectief en levert niche-/marktkennis op
 - Wat is de domeinspecifieke cultuur?
 - Overstijg het 'generische': wat is belangrijk in HUN sector?
 - Wie zijn HUN klanten? Wat is HUN Rol? (verkoop, prijszetting)
- Financiering
 - Verkoop, prijszetting, vermarkting
 - Partnerschappen, pilootprojecten, co-ontwikkeling
 - Gezamenlijke subsidieproposals (VLAIO, EU,....)
 - Participaties en exit opportuniteit
- Human resources
 - Recrutering
 - Board members (caveat: Col!)
 - Biotoop van markt